Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

First Posted Date
2023-11-15
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
710
Registration Number
NCT06132958
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Arizona Oncology Associates - HOPE ( Site 8002), Tucson, Arizona, United States

๐Ÿ‡จ๐Ÿ‡ฟ

Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1705), Praha, Praha 2, Czechia

๐Ÿ‡บ๐Ÿ‡ธ

USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama, United States

and more 220 locations

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

First Posted Date
2023-11-01
Last Posted Date
2024-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
1728
Registration Number
NCT06112379
Locations
๐Ÿ‡ป๐Ÿ‡ณ

Research Site, Vinh, Vietnam

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

First Posted Date
2023-10-31
Last Posted Date
2024-06-04
Lead Sponsor
University of Chicago
Target Recruit Count
42
Registration Number
NCT06110195
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

First Posted Date
2023-10-30
Last Posted Date
2024-03-22
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
24
Registration Number
NCT06107868
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

First Posted Date
2023-10-27
Last Posted Date
2024-11-25
Lead Sponsor
AstraZeneca
Target Recruit Count
625
Registration Number
NCT06103864
Locations
๐Ÿ‡ป๐Ÿ‡ณ

Research Site, Vinh, Vietnam

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

First Posted Date
2023-10-24
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
304
Registration Number
NCT06096844
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Highlands Oncology Group - Rogers, Rogers, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Highlands Oncology Group, Springdale, Arkansas, United States

and more 219 locations

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2023-10-23
Last Posted Date
2024-10-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1
Registration Number
NCT06094296
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0058, Boise, Idaho, United States

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0044, Clermont, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0049, Houston, Texas, United States

and more 5 locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

First Posted Date
2023-10-10
Last Posted Date
2024-12-19
Lead Sponsor
Verastem, Inc.
Target Recruit Count
270
Registration Number
NCT06072781
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Texas Oncology Central, Austin, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center, Houston, Texas, United States

and more 58 locations

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

First Posted Date
2023-10-04
Last Posted Date
2024-01-23
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
45
Registration Number
NCT06066216

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

First Posted Date
2023-10-02
Last Posted Date
2023-10-06
Lead Sponsor
Presage Biosciences
Target Recruit Count
15
Registration Number
NCT06062602
Locations
๐Ÿ‡บ๐Ÿ‡ธ

LSU Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Pennsylvania, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Cincinnati Health, Cincinnati, Ohio, United States

and more 1 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy